(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 August 2007 (02.08.2007)

PCT

(10) International Publication Number
WO 2007/085833 A3

(51) International Patent Classification:
C07D 239/48 (2006.01) *C07D 413/12* (2006.01)
C07D 403/12 (2006.01) *A61P 35/00* (2006.01)
C07D 405/12 (2006.01)

(21) International Application Number:
PCT/GB2007/000251

(22) International Filing Date: 25 January 2007 (25.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/762,387 26 January 2006 (26.01.2006) US

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KETTLE, Jason, Grant** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **READ, Jon** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **LEACH, Andrew** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **BARLAAM, Bernard, Christophe** [FR/FR]; AstraZeneca Reims, Z.I. La Pompelle, BP 1050 Cedex 2, F-51689 Reims (FR). **DUCRAY, Richard** [FR/FR]; AstraZeneca Reims, Z.I. La Pompelle, BP 1050 Cedex 2, F-51689 Reims (FR). **LAMBERT-VAN DER BREMPT, Christine, Marie Paul** [BE/FR]; AstraZeneca Reims, Z.I. La Pompelle, BP 1050 Cedex 2, F-51689 Reims (FR).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; Astrazeneca AB, S-SE-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
27 September 2007

[Continued on next page]

(54) Title: PYRIMIDINE DERIVATIVES



(I)

(57) Abstract: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R^1, ring A, n, R^3, and R^4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

WO 2007/085833 A3

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.